Debt-to-equity in % of Mersana Therapeutics, Inc. from Q2 2019 to Q3 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Mersana Therapeutics, Inc. quarterly Debt-to-equity history and change rate from Q2 2019 to Q3 2025.
Mersana Therapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -364 %, a 139% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Mersana Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q3 2025	-364	-1.3K	-139%	30 Sep 2025
Q2 2025	-653	-1.24K	-211%	30 Jun 2025
Q1 2025	-2.06K	-2.44K	-639%	31 Mar 2025
Q4 2024	2.37K	+2.02K	+577%	31 Dec 2024
Q3 2024	940	+636	+209%	30 Sep 2024
Q2 2024	590	+317	+116%	30 Jun 2024
Q1 2024	383	+168	+78.2%	31 Mar 2024
Q4 2023	351	+197	+128%	31 Dec 2023
Q3 2023	304	+192	+171%	30 Sep 2023
Q2 2023	274	+204	+295%	30 Jun 2023
Q1 2023	215	+162	+309%	31 Mar 2023
Q4 2022	154	+116	+305%	31 Dec 2022
Q3 2022	112	+84.3	+304%	30 Sep 2022
Q2 2022	69.3	+47.6	+219%	30 Jun 2022
Q1 2022	52.6	+34.8	+196%	31 Mar 2022
Q4 2021	38	+19.4	+104%	31 Dec 2021
Q3 2021	27.7	+7.42	+36.5%	30 Sep 2021
Q2 2021	21.8	-3.36	-13.4%	30 Jun 2021
Q1 2021	17.7	-17.7	-49.9%	31 Mar 2021
Q4 2020	18.6	-9.66	-34.2%	31 Dec 2020
Q3 2020	20.3	-25.9	-56%	30 Sep 2020
Q2 2020	25.1	-45.1	-64.2%	30 Jun 2020
Q1 2020	35.4			31 Mar 2020
Q4 2019	28.2			31 Dec 2019
Q3 2019	46.2			30 Sep 2019
Q2 2019	70.2			30 Jun 2019

* An asterisk sign (*) next to the value indicates that the value is likely invalid.